Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stock Report

Market Cap: US$9.2b

Arrowhead Pharmaceuticals Management

Management criteria checks 2/4

Arrowhead Pharmaceuticals' CEO is Chris Anzalone, appointed in Dec 2007, has a tenure of 18.08 years. total yearly compensation is $12.42M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 2.8% of the company’s shares, worth $258.00M. The average tenure of the management team and the board of directors is 4 years and 14.1 years respectively.

Key information

Chris Anzalone

Chief executive officer

US$12.4m

Total compensation

CEO salary percentage7.65%
CEO tenure18.1yrs
CEO ownership2.8%
Management average tenure4yrs
Board average tenure14.1yrs

Recent management updates

Recent updates

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Dec 02
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade)

Nov 27

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Oct 07
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Aug 21
Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified
User avatar

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

May 14
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

May 03
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 21

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Feb 10

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

CEO Compensation Analysis

How has Chris Anzalone's remuneration changed compared to Arrowhead Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$2m

Jun 30 2025n/an/a

-US$148m

Mar 31 2025n/an/a

-US$144m

Dec 31 2024n/an/a

-US$640m

Sep 30 2024US$12mUS$951k

-US$599m

Jun 30 2024n/an/a

-US$539m

Mar 31 2024n/an/a

-US$471m

Dec 31 2023n/an/a

-US$297m

Sep 30 2023US$10mUS$903k

-US$205m

Jun 30 2023n/an/a

-US$181m

Mar 31 2023n/an/a

-US$150m

Dec 31 2022n/an/a

-US$155m

Sep 30 2022US$12mUS$863k

-US$176m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$183m

Sep 30 2021US$25mUS$837k

-US$141m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020n/an/a

-US$103m

Sep 30 2020US$14mUS$786k

-US$85m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

US$10m

Dec 31 2019n/an/a

US$53m

Sep 30 2019US$2mUS$674k

US$68m

Compensation vs Market: Chris's total compensation ($USD12.42M) is above average for companies of similar size in the US market ($USD8.28M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Anzalone (56 yo)

18.1yrs
Tenure
US$12,423,473
Compensation

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007 and serves as its Chairman. He serves a...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Anzalone
Chairman18.1yrsUS$12.42m2.8%
$ 258.0m
Patrick O'Brien
COO, General Counsel & Secretary11.1yrsUS$3.93m0.23%
$ 21.4m
James Hamilton
Chief Medical Officer and Head of R&Dno dataUS$3.49m0.16%
$ 14.4m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Daniel Apel
Chief Financial Officerless than a yearno data0.00088%
$ 81.1k
Vincent Anzalone
Head of Investor Relations & VPno datano datano data
Howard Lovy
Director of Communications20.4yrsno datano data
Bruce Given
Chief Medical Scientist1.9yrsUS$16.34mno data
Mark Seefeld
Head of Toxicology & VPno datano datano data
Aaron Tan
Head of Tax4yrsno datano data
Andy Davis
SVP of Cardiovascular & Head of Metabolic Franchise1.2yrsno datano data
Nadia Meshkova
VP & Treasurer4yrsno datano data
4.0yrs
Average Tenure
61yo
Average Age

Experienced Management: ARWR's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Anzalone
Chairman18.1yrsUS$12.42m2.8%
$ 258.0m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Michael Perry
Independent Director14.1yrsUS$460.83k0.072%
$ 6.7m
William Waddill
Independent Lead Director8yrsUS$470.83k0.036%
$ 3.3m
Ching-Lung Lai
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Robert Gish
Chairman of Hepatitis B Clinical Advisory Boardno datano datano data
Mauro Ferrari
Independent Director15.4yrsUS$460.83k0.045%
$ 4.2m
Jeffrey Teckman
Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Boardno datano datano data
Stephen Locarnini
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Johnson Y. Lau
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Carlo Ferrari
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Victoria Vakiener
Independent Director3.7yrsUS$460.83k0.021%
$ 1.9m
14.1yrs
Average Tenure
66yo
Average Age

Experienced Board: ARWR's board of directors are seasoned and experienced ( 14.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/04 08:35
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
William PickeringBernstein
Jason Matthew GerberryBofA Global Research